

Datasheet: MCA400

BATCH NUMBER 158183

| | |
|----------------------|--------------------------------------|
| Description: | MOUSE ANTI INFLUENZA A NUCLEOPROTEIN |
| Specificity: | INFLUENZA A NUCLEOPROTEIN |
| Format: | Purified |
| Product Type: | Monoclonal Antibody |
| Clone: | AA5H |
| Isotype: | IgG2a |
| Quantity: | 1 mg |

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

| | Yes | No | Not Determined | Suggested Dilution |
|----------------------------|-----|----|----------------|--------------------|
| Flow Cytometry | | | ▪ | |
| Immunohistology - Frozen | | | ▪ | |
| Immunohistology - Paraffin | ▪ | | | |
| ELISA | | | ▪ | |
| Immunoprecipitation | | | ▪ | |
| Western Blotting | ▪ | | | |
| Immunofluorescence | ▪ | | | |

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

| | |
|---------------------------------|--|
| Target Species | Viral |
| Product Form | Purified IgG - liquid |
| Preparation | Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant. |
| Buffer Solution | Phosphate buffered saline |
| Preservative Stabilisers | 0.09% Sodium Azide |
| Approx. Protein | IgG concentration 1.0 mg/ml |

Concentrations

Immunogen Influenza A / Puerto Rico / 8 / 34 (H1N1) and A/Bangkok / 1 / 79 (H3N2) viruses.

RRID AB_2151884

Fusion Partners Spleen cells from BALB/c mice were fused with cells of the P3 Ag8.653 mouse myeloma cell line.

Specificity **Mouse anti Influenza A Nucleoprotein antibody, clone AA5H** recognizes an epitope within Influenza virus A nucleoprotein. Mouse anti Influenza A Nucleoprotein antibody, clone AA5H can be used in influenza A IFA typing in conjunction with [MCA401](#) (clone GA2B).

References

1. Herold, S. *et al.* (2006) Alveolar epithelial cells direct monocyte transepithelial migration upon influenza virus infection: impact of chemokines and adhesion molecules. [J Immunol. 177 \(3\): 1817-24.](#)
2. Ehrhardt, C. *et al.* (2007) Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses. [J Virol. 81: 3058-67.](#)
3. Ehrhardt, C. *et al.* (2007) Activation of phosphatidylinositol 3-kinase signaling by the nonstructural NS1 protein is not conserved among type A and B influenza viruses. [J Virol. 81: 12097-100.](#)
4. Matarrese, P. *et al.* (2011) Pepstatin A alters host cell autophagic machinery and leads to a decrease in influenza A virus production. [J Cell Physiol. 226 \(12\): 3368-77.](#)
5. Nencioni, L. *et al.* (2009) Bcl-2 expression and p38MAPK activity in cells infected with influenza A virus: impact on virally induced apoptosis and viral replication. [J Biol Chem. 284: 16004-15.](#)
6. Pauli, E.K. *et al.* (2008) Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. [PLoS Pathog. 4\(11\): e1000196.](#)
7. Jamali, A. *et al.* (2010) A DNA vaccine-encoded nucleoprotein of influenza virus fails to induce cellular immune responses in a diabetic mouse model. [Clin Vaccine Immunol. 17: 683-7.](#)
8. Ehrhardt, C. *et al.* (2007) A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. [Antiviral Res. 76: 38-47.](#)
9. Seitz, C. *et al.* (2010) High yields of influenza A virus in Madin-Darby canine kidney cells are promoted by an insufficient interferon-induced antiviral state. [J Gen Virol. 91: 1754-63.](#)
10. Gabay, C. *et al.* (2011) Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. [Arthritis Rheum. 63 \(6\): 1486-96.](#)
11. Luig, C. *et al.* (2010) MAP kinase-activated protein kinases 2 and 3 are required for influenza A virus propagation and act via inhibition of PKR. [FASEB J. 24: 4068-77.](#)
12. Shu, Y. *et al.* (2010) Avian influenza A(H5N1) viruses can directly infect and replicate in human gut tissues. [J Infect Dis. 201: 1173-7.](#)
13. Hassan, I.H. *et al.* (2012) Influenza A viral replication is blocked by inhibition of the inositol-requiring enzyme 1 (IRE1) stress pathway. [J Biol Chem. 287 \(7\): 4679-89.](#)

14. Brnic, D. *et al.* (2012) Borna disease virus infects human neural progenitor cells and impairs neurogenesis. [J Virol. 86 \(5\): 2512-22.](#)
15. Hrinčius, E.R. *et al.* (2011) Phosphatidylinositol-3-kinase (PI3K) is activated by influenza virus vRNA via the pathogen pattern receptor Rig-I to promote efficient type I interferon production. [Cell Microbiol. 13: 1907-19.](#)
16. Koerner, I. *et al.* (2012) Altered receptor specificity and fusion activity of the haemagglutinin contribute to high virulence of a mouse-adapted influenza A virus. [J Gen Virol. 93 \(Pt 5\): 970-9.](#)
17. Thompson, C.I. *et al.* (2006) Infection of human airway epithelium by human and avian strains of influenza a virus. [J Virol. 80: 8060-8.](#)
18. Gao, R. *et al.* (2010) A systematic molecular pathology study of a laboratory confirmed H5N1 human case. [PLoS One. 5: e13315.](#)
19. Matthaei M *et al.* (2013) Highly pathogenic H5N1 influenza A virus strains provoke heterogeneous IFN- α/β responses that distinctively affect viral propagation in human cells. [PLoS One. 8 \(2\): e56659.](#)
20. Wörmann, X. *et al.* (2016) Genetic characterization of an adapted pandemic 2009 H1N1 influenza virus that reveals improved replication rates in human lung epithelial cells [Virology. 492: 118-29.](#)
21. Sadewasser, A. *et al.* (2017) Quantitative proteomic approach identifies Vpr binding protein as novel host factor supporting influenza A virus infections in human cells. [Mol Cell Proteomics. pii: mcp.M116.065904. \[Epub ahead of print\]](#)
22. Kim HR *et al.* (2016) Ostrich (*Struthio camelus*) Infected with H5N8 Highly Pathogenic Avian Influenza Virus in South Korea in 2014. [Avian Dis. 60 \(2\): 535-9.](#)
23. Dick, A. *et al.* (2015) Role of nucleotide binding and GTPase domain dimerization in dynamin-like myxovirus resistance protein A for GTPase activation and antiviral activity. [J Biol Chem. 290 \(20\): 12779-92.](#)
24. Shoji, M. *et al.* (2015) Bakuchiol Is a Phenolic Isoprenoid with Novel Enantiomer-selective Anti-influenza A Virus Activity Involving Nrf2 Activation. [J Biol Chem. 290 \(46\): 28001-17.](#)
25. Thulasi Raman, S.N. *et al.* (2016) DDX3 Interacts with Influenza A Virus NS1 and NP Proteins and Exerts Antiviral Function through Regulation of Stress Granule Formation. [J Virol. 90 \(7\): 3661-75.](#)
26. Youchan, B. *et al.* (2018) Pathological lesions and antigen localization in chicken, ducks and Japanese quail naturally infected by novel highly pathogenic avian influenza (H5N6), Korea, 2016 [J Prev Vet Med. 42 \(3\): 91-8.](#)
27. Sid, H. *et al.* (2017) Interaction of Influenza A Viruses with Oviduct Explants of Different Avian Species. [Front Microbiol. 8: 1338.](#)
28. Prokopyeva, E.A. *et al.* (2019) Pathology of A(H5N8) (Clade 2.3.4.4) Virus in Experimentally Infected Chickens and Mice. [Interdiscip Perspect Infect Dis. 2019: 4124865.](#)
29. Calmy, A. *et al.* (2012) Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients. [HIV Med. 13 \(4\): 207-18.](#)

Storage

Store at +4°C or at -20°C if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing

as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

| | |
|------------------|---------------------------------|
| Guarantee | 12 months from date of despatch |
|------------------|---------------------------------|

| | |
|--------------------------------------|--|
| Health And Safety Information | Material Safety Datasheet documentation #10040 available at: https://www.bio-rad-antibodies.com/SDS/MCA400 10040 |
|--------------------------------------|--|

| | |
|-------------------|----------------------------|
| Regulatory | For research purposes only |
|-------------------|----------------------------|

Related Products

Recommended Secondary Antibodies

| | |
|---|---|
| Rabbit Anti Mouse IgG (STAR12...) | RPE |
| Goat Anti Mouse IgG IgA IgM (STAR87...) | HRP |
| Goat Anti Mouse IgG (STAR76...) | RPE |
| Goat Anti Mouse IgG (STAR70...) | FITC |
| Goat Anti Mouse IgG (H/L) (STAR117...) | Alk. Phos. , DyLight®488 , DyLight®550 , DyLight®650 , DyLight®680 , DyLight®800 , FITC , HRP |
| Rabbit Anti Mouse IgG (STAR9...) | FITC |
| Goat Anti Mouse IgG (STAR77...) | HRP |
| Goat Anti Mouse IgG (Fc) (STAR120...) | FITC , HRP |
| Rabbit Anti Mouse IgG (STAR13...) | HRP |

| | | | | | |
|----------------------------------|---|------------------|---|---------------|---|
| North & South America | Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com | Worldwide | Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com | Europe | Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com |
|----------------------------------|---|------------------|---|---------------|---|

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

'M367650:200529'

Printed on 13 Mar 2024